![]()
- Tiger Woods Injured in Florida Car Accident
- Dubai Stock Selloff May Bring Buying Opportunity
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
- Longer Lines, Fuller Carts This Black Friday
- Get Paid Six Figures to Wear a T-Shirt?
- The World's Biggest Debtor Nations
- Five Tips for Buying a Foreclosed Home
- Slideshow: Fantasy Christmas Gifts 2009
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- 8 Retailers that Gain During the Holidays
MOST SHARED
- 8 Retailers that Gain During the Holidays
- Get Paid Six Figures to Wear a T-Shirt?
- Dubai Spooks Investors But May Bring Buying Opportunity
- Finding the Holiday's Best Buys
- Tiger Woods Seriously Injured in Car Accident
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Longer Lines, Fuller Carts This Black Friday
- Banks Play Down Dubai Exposure, Investors Still Wary
- The Good Entrepreneur Winner
- Global Selloff From Dubai Woes Shows Signs of Winding Down
How's the health of Big Pharma? Not bad, judging from Pfizer, Eli Lilly and Wyeth results. Still, the drug market leaders could use some diet and exercise, here and there ...
Pfizer
"Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians," Chief Executive Jeff Kindler said in a release. "We have therefore concluded that further investment in this product is unwarranted."
That cost the drug maker $2.8 billion in the third quarter. It [PFE
Loading...
()
] was also hurt by declining sales of cholesterol fighter Lipitor and generic competition for many of Pfizer's other medicines.
Still, excluding special items profit was 58 cents per share for the world's largest drug maker. Analysts on average expected 52 cents, according to Reuters Estimates. (Full report on Pfizer's results here).
Eli Lilly
The Indianapolis-based drugmaker on Thursday posted a 6 percent rise in quarterly profit on higher sales of newer prescription drugs, including its Cymbalta anti-depressant. It also raised its 2007 forecast, saying it expects sales growth to outpace operating expenses.
Lilly CEO John Lechleiter said on this morning's "Squawk Box" that the company has made progress developing several of its drugs awaiting Food and Drug Administration approval, and is expecting the momentum to carry over to solid fourth-quarter results.
"We’ve gotten great top-line performance this year," Lechleiter said. "This is the best volume growth that we’ve had since 2001."
Excluding a charge of 6 cents per share related to insurance recoveries, Lilly [LLY
Loading...
()
] earned 91 cents per share. Analysts on average expected 87 cents, according to Reuters Estimates. (Full story on Lilly's results here.)
Wyeth
Wyeth said Thursday that third-quarter earnings fell slightly, hurt by charges tied to productivity initiatives that offset higher sales of its pharmaceutical products.
Wyeth [WYE
Loading...
()
], which has endured a string of setbacks to its experimental drugs, also launched a $5 billion stock buyback program. (Read full Wyeth report here).
Novartis
In a report late Wednesday, Swiss drugmaker Novartis's third-quarter net profit missed forecasts, dropping by 12 percent to $1.57 billion, weighed down by the launch of rival generic versions of its drugs and a one-off charge.
But its shares opened 0.5 percent higher, as markets reacted positively to 1,260 job cuts in the United States and analysts said the underlying business still looked sound.
"The weaker third-quarter results mark the bottoming out for Novartis, in our opinion," said Philipp Buchli, a fund manager at Q Investments in Zurich. (Read more about Novartis here).
- These four sectors will be the next to lead the market.
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- It may be the most unusual guide to business you'll read.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?













